Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
dear newbies,this is a brief pump, prepare for the dump, maximize profits =).
I hate companies like BRZG that dont make any money...why? because I hate making no money!! =(
$$$$$$ BMSN NEWSSSS $$$$$$$$$$
GET READY FOR BOOOOOOOOOOMSN!!!!!
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Benitec License to Expand the Scope of the Company's Cancer Vaccine Patent Portfolio; Regen Developing Cancer Vaccines Based on Gene Silenced Dendritic Cells; Breast Cancer to Be First Target for Therapy
SAN DIEGO, CA--(Marketwired - Aug 8, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.
Benitec's licence to Regen covers the application of ddRNAi to silence indoleamine 2,3 -- dioxygenase (IDO) in Dendritic Cells. IDO is associated with immune-suppression and is over-expressed in cancer. Regen has produced pre-clinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO should significantly enhance their efficacy as anti-cancer vaccine agents. A peer-reviewed publication describing this work was published in the February 2013 issue of the International Journal of Cancer ( Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77) . While the terms are commercial-in-confidence, they are within the expected guidelines for small biotechnology companies in the early stage of therapeutic development, with fees based on the achievement of agreed milestones.
Chief Executive Officer of Benitec Biopharma Ltd, Dr. Peter French, commented, "Benitec is very pleased to have executed this licensing deal with Regen BioPharma. Using ddRNAi to manipulate Dendritic Cells to stimulate the immune system to kill cancer cells is an innovative concept for the treatment of cancer in a non-toxic manner. Regen joins a growing list of biotechnology companies that have recognised the advantage of licensing Benitec's transformational gene silencing technology, ddRNAi, to develop novel therapies for human disease. For Benitec this provides the opportunity to generate additional evidence that validates and reinforces the potential of our platform technology."
Chairman & Chief Executive Officer of Regen BioPharma, Dr. David Koos, commented, " Benitec is the leader in clinical development of ddRNAi, which allows for 'gene-specific surgery.' By combining our existing data with the issued patents and experience of Benitec, we look forward to developing an immune-based, non-toxic, cancer treatment initially targeting breast cancer ."
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com .
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
$$$$$$ BMSN NEWSSSS $$$$$$$$$$
GET READY FOR BOOOOOOOOOOMSN!!!!!
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Benitec License to Expand the Scope of the Company's Cancer Vaccine Patent Portfolio; Regen Developing Cancer Vaccines Based on Gene Silenced Dendritic Cells; Breast Cancer to Be First Target for Therapy
SAN DIEGO, CA--(Marketwired - Aug 8, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.
Benitec's licence to Regen covers the application of ddRNAi to silence indoleamine 2,3 -- dioxygenase (IDO) in Dendritic Cells. IDO is associated with immune-suppression and is over-expressed in cancer. Regen has produced pre-clinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO should significantly enhance their efficacy as anti-cancer vaccine agents. A peer-reviewed publication describing this work was published in the February 2013 issue of the International Journal of Cancer ( Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77) . While the terms are commercial-in-confidence, they are within the expected guidelines for small biotechnology companies in the early stage of therapeutic development, with fees based on the achievement of agreed milestones.
Chief Executive Officer of Benitec Biopharma Ltd, Dr. Peter French, commented, "Benitec is very pleased to have executed this licensing deal with Regen BioPharma. Using ddRNAi to manipulate Dendritic Cells to stimulate the immune system to kill cancer cells is an innovative concept for the treatment of cancer in a non-toxic manner. Regen joins a growing list of biotechnology companies that have recognised the advantage of licensing Benitec's transformational gene silencing technology, ddRNAi, to develop novel therapies for human disease. For Benitec this provides the opportunity to generate additional evidence that validates and reinforces the potential of our platform technology."
Chairman & Chief Executive Officer of Regen BioPharma, Dr. David Koos, commented, " Benitec is the leader in clinical development of ddRNAi, which allows for 'gene-specific surgery.' By combining our existing data with the issued patents and experience of Benitec, we look forward to developing an immune-based, non-toxic, cancer treatment initially targeting breast cancer ."
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com .
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
$$$$$$ BMSN NEWSSSS $$$$$$$$$$
GET READY FOR BOOOOOOOOOOMSN!!!!!
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Benitec License to Expand the Scope of the Company's Cancer Vaccine Patent Portfolio; Regen Developing Cancer Vaccines Based on Gene Silenced Dendritic Cells; Breast Cancer to Be First Target for Therapy
SAN DIEGO, CA--(Marketwired - Aug 8, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.
Benitec's licence to Regen covers the application of ddRNAi to silence indoleamine 2,3 -- dioxygenase (IDO) in Dendritic Cells. IDO is associated with immune-suppression and is over-expressed in cancer. Regen has produced pre-clinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO should significantly enhance their efficacy as anti-cancer vaccine agents. A peer-reviewed publication describing this work was published in the February 2013 issue of the International Journal of Cancer ( Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77) . While the terms are commercial-in-confidence, they are within the expected guidelines for small biotechnology companies in the early stage of therapeutic development, with fees based on the achievement of agreed milestones.
Chief Executive Officer of Benitec Biopharma Ltd, Dr. Peter French, commented, "Benitec is very pleased to have executed this licensing deal with Regen BioPharma. Using ddRNAi to manipulate Dendritic Cells to stimulate the immune system to kill cancer cells is an innovative concept for the treatment of cancer in a non-toxic manner. Regen joins a growing list of biotechnology companies that have recognised the advantage of licensing Benitec's transformational gene silencing technology, ddRNAi, to develop novel therapies for human disease. For Benitec this provides the opportunity to generate additional evidence that validates and reinforces the potential of our platform technology."
Chairman & Chief Executive Officer of Regen BioPharma, Dr. David Koos, commented, " Benitec is the leader in clinical development of ddRNAi, which allows for 'gene-specific surgery.' By combining our existing data with the issued patents and experience of Benitec, we look forward to developing an immune-based, non-toxic, cancer treatment initially targeting breast cancer ."
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com .
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
$$$$$$ BMSN NEWSSSS $$$$$$$$$$
GET READY FOR BOOOOOOOOOOMSN!!!!!
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Benitec License to Expand the Scope of the Company's Cancer Vaccine Patent Portfolio; Regen Developing Cancer Vaccines Based on Gene Silenced Dendritic Cells; Breast Cancer to Be First Target for Therapy
SAN DIEGO, CA--(Marketwired - Aug 8, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.
Benitec's licence to Regen covers the application of ddRNAi to silence indoleamine 2,3 -- dioxygenase (IDO) in Dendritic Cells. IDO is associated with immune-suppression and is over-expressed in cancer. Regen has produced pre-clinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO should significantly enhance their efficacy as anti-cancer vaccine agents. A peer-reviewed publication describing this work was published in the February 2013 issue of the International Journal of Cancer ( Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77) . While the terms are commercial-in-confidence, they are within the expected guidelines for small biotechnology companies in the early stage of therapeutic development, with fees based on the achievement of agreed milestones.
Chief Executive Officer of Benitec Biopharma Ltd, Dr. Peter French, commented, "Benitec is very pleased to have executed this licensing deal with Regen BioPharma. Using ddRNAi to manipulate Dendritic Cells to stimulate the immune system to kill cancer cells is an innovative concept for the treatment of cancer in a non-toxic manner. Regen joins a growing list of biotechnology companies that have recognised the advantage of licensing Benitec's transformational gene silencing technology, ddRNAi, to develop novel therapies for human disease. For Benitec this provides the opportunity to generate additional evidence that validates and reinforces the potential of our platform technology."
Chairman & Chief Executive Officer of Regen BioPharma, Dr. David Koos, commented, " Benitec is the leader in clinical development of ddRNAi, which allows for 'gene-specific surgery.' By combining our existing data with the issued patents and experience of Benitec, we look forward to developing an immune-based, non-toxic, cancer treatment initially targeting breast cancer ."
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com .
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
$$$$$$ BMSN NEWSSSS $$$$$$$$$$
GET READY FOR BOOOOOOOOOOMSN!!!!!
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Benitec License to Expand the Scope of the Company's Cancer Vaccine Patent Portfolio; Regen Developing Cancer Vaccines Based on Gene Silenced Dendritic Cells; Breast Cancer to Be First Target for Therapy
SAN DIEGO, CA--(Marketwired - Aug 8, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.
Benitec's licence to Regen covers the application of ddRNAi to silence indoleamine 2,3 -- dioxygenase (IDO) in Dendritic Cells. IDO is associated with immune-suppression and is over-expressed in cancer. Regen has produced pre-clinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO should significantly enhance their efficacy as anti-cancer vaccine agents. A peer-reviewed publication describing this work was published in the February 2013 issue of the International Journal of Cancer ( Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77) . While the terms are commercial-in-confidence, they are within the expected guidelines for small biotechnology companies in the early stage of therapeutic development, with fees based on the achievement of agreed milestones.
Chief Executive Officer of Benitec Biopharma Ltd, Dr. Peter French, commented, "Benitec is very pleased to have executed this licensing deal with Regen BioPharma. Using ddRNAi to manipulate Dendritic Cells to stimulate the immune system to kill cancer cells is an innovative concept for the treatment of cancer in a non-toxic manner. Regen joins a growing list of biotechnology companies that have recognised the advantage of licensing Benitec's transformational gene silencing technology, ddRNAi, to develop novel therapies for human disease. For Benitec this provides the opportunity to generate additional evidence that validates and reinforces the potential of our platform technology."
Chairman & Chief Executive Officer of Regen BioPharma, Dr. David Koos, commented, " Benitec is the leader in clinical development of ddRNAi, which allows for 'gene-specific surgery.' By combining our existing data with the issued patents and experience of Benitec, we look forward to developing an immune-based, non-toxic, cancer treatment initially targeting breast cancer ."
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com .
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
keeps the flippers away
New$$$ out in BMSN !!!
http://www.benitec.com/documents/REGENLICENCEFORCANCERVACCINES.pdf
Benitec Biopharma licenses ddRNAi technology to Regen
BioPharma Inc for the development of Cancer Vaccines
Key Points:
US-based biotechnology developing cancer vaccines based on Dendritic Cells
License allows further investigation of Benitec's ddRNAi technology's role in silencing an immunodulatory molecule (IDO) that is over-expressed in cancer
Sydney Australia, Tuesday 6 August 2013. Benitec Biopharma Ltd (ASX: BLT) is pleased to announce that it has entered into a licensing agreement with San Diego (US) based Regen BioPharma Inc a subsidiary of Bio-Matrix (OTCQB:BMSN). Benitec's exclusive licence allows Regen to develop cancer vaccines using Benitec's ddRNAi gene silencing technology.
Benitec's licence to Regen covers the application of ddRNAi to silence indoleamine 2,3 - doxygenase (IDO) in Dendritic Cells. IDO is associated with immune-suppression and is over-expressed in cancer. Regen has produced pre-clinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO should significantly enhance their efficacy as anti-cancer vaccine agents. A peer-reviewed publication describing this work was published in the February 2013 volume of the International Journal of Cancer (Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77).Whilst the terms are commercial-in-confidence, they are within the expected guidelines for small biotech companies in the early stage of therapeutic development, with fees based on the achievement of agreed milestones.
Chief Executive Officer of Benitec Biopharma Ltd, Dr Peter French, commented, "Benitec is very pleased to have executed this licensing deal with Regen BioPharma. Using ddRNAi to manipulate Dendritic Cells to stimulate the immune system to kill cancer cells is an innovative concept for the treatment of cancer in a non-toxic manner. Regen joins a growing list of biotechnology companies that have recognised the advantage of licensing Benitec's transformational gene silencing technology, ddRNAi, to develop novel therapies for human disease. For Benitec this provides the opportunity to generate additional evidence that validates and reinforces the potential of our platform technology."
Chairman & Chief Executive Officer of Regen BioPharma, Dr. David Koos, commented, "Benitec is the leader in clinical development of ddRNAi, which allows for "gene-specific surgery". By combining our existing data with the issued patents and experience of Benitec, we look forward to developing an immune-based, non-toxic, cancer treatment initially targeting breast cancer."
For more information please contact: Carl Stubbings | Chief Business Officer
Phone: +61 (02) 9555 6986 | cstubbings@benitec.com | www.benitec.com
About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
New$$$ out in BMSN !!!
http://www.benitec.com/documents/REGENLICENCEFORCANCERVACCINES.pdf
Benitec Biopharma licenses ddRNAi technology to Regen
BioPharma Inc for the development of Cancer Vaccines
Key Points:
US-based biotechnology developing cancer vaccines based on Dendritic Cells
License allows further investigation of Benitec's ddRNAi technology's role in silencing an immunodulatory molecule (IDO) that is over-expressed in cancer
Sydney Australia, Tuesday 6 August 2013. Benitec Biopharma Ltd (ASX: BLT) is pleased to announce that it has entered into a licensing agreement with San Diego (US) based Regen BioPharma Inc a subsidiary of Bio-Matrix (OTCQB:BMSN). Benitec's exclusive licence allows Regen to develop cancer vaccines using Benitec's ddRNAi gene silencing technology.
Benitec's licence to Regen covers the application of ddRNAi to silence indoleamine 2,3 - doxygenase (IDO) in Dendritic Cells. IDO is associated with immune-suppression and is over-expressed in cancer. Regen has produced pre-clinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO should significantly enhance their efficacy as anti-cancer vaccine agents. A peer-reviewed publication describing this work was published in the February 2013 volume of the International Journal of Cancer (Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77).Whilst the terms are commercial-in-confidence, they are within the expected guidelines for small biotech companies in the early stage of therapeutic development, with fees based on the achievement of agreed milestones.
Chief Executive Officer of Benitec Biopharma Ltd, Dr Peter French, commented, "Benitec is very pleased to have executed this licensing deal with Regen BioPharma. Using ddRNAi to manipulate Dendritic Cells to stimulate the immune system to kill cancer cells is an innovative concept for the treatment of cancer in a non-toxic manner. Regen joins a growing list of biotechnology companies that have recognised the advantage of licensing Benitec's transformational gene silencing technology, ddRNAi, to develop novel therapies for human disease. For Benitec this provides the opportunity to generate additional evidence that validates and reinforces the potential of our platform technology."
Chairman & Chief Executive Officer of Regen BioPharma, Dr. David Koos, commented, "Benitec is the leader in clinical development of ddRNAi, which allows for "gene-specific surgery". By combining our existing data with the issued patents and experience of Benitec, we look forward to developing an immune-based, non-toxic, cancer treatment initially targeting breast cancer."
For more information please contact: Carl Stubbings | Chief Business Officer
Phone: +61 (02) 9555 6986 | cstubbings@benitec.com | www.benitec.com
About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
you mean the less than 2 million share dilution dump? because the A/S is STILL 2 billion
So what do all the naysayers have to say about PG speaking with the company now?
Usually nothing happens on Fridays, even with news Fridays could be quite the full day. It's all for profit taking for the weekend, little sells for liquor.
hi jack.....
CAPTAIN WHERE ART THOU If its anything, the otc markets website was down earlier today at around 12pm pacific.
Entb is nice because of the share structure so the PPS could fluctuate more. But remember fluctuation has 2 sides....
I dunno about deleted.... Merged is more likely
Yes an r/s would kill bmsn
In the near future? Not without an R/S. very very long term after multiple phase 2 drug sells...definitely
Agreed 100%
Who's to say that the 800 mill diluted can't pay for both?
Who's to say that the VNDM on the ask isn't retail?
Whoever gets in below 0.0017 is SMART MONEY!! We're headed to the 4s ARGHHH
SMART $$$ MONEY is whoever gets in below 0.0017! 0.004 $hip$ $et $ail!! Northward bound!
JACK you ever listen to the $eagull$ in the mornin'? THEY squawk MER-----GER$$$$$$$$$$$$$$$$$$
Meds became fully reporting again, entb became fully reporting, and BMSN has ALWAYS been. ALLLLL are connected in some way too.
I'm so excited to watch entb in the coming days!
How's that BMSN lookin'?
Waterloo science alumni rejoice!
how can you transfer FDA approval?
ARGHHHH can't be missin' thar ships matey! POOOOOORRR Sabai... Maybe if you wereNT a wee lil flipper you coulda stayed for the $et $$$$$$ail!!!!
Oh, we know. We know :)
0.0031-0.0030=0.0001 ! THE DIFFERENCE!
Take that 5k and buy a laptop
liquid! liquid! liquid!
go read my pm =)
he's never bad or good. He just tells whats happening, as you can clearly see.
STICKY
This post should be perma-stickied. So much time and effort was placed into this to get minimal recognition now. I have absolutely no idea why it isn't.
Sorry. You're correct.
Quarter 3 was INITIATION of trials. Not approval. Big difference.